NovoCure engages in the development, manufacture and commercialization of tumor treating fields for the treatment of solid tumors. The Company markets its proprietary therapy, TTFields delivery system, for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Jersey, JE
Size (employees)
460 (est)
NovoCure was founded in 2000 and is headquartered in Jersey, JE
Report incorrect company information

Key People/Management at NovoCure

Bill Burke

Bill Burke

Global Head HR
Laura Benson

Laura Benson

Vice President Medical Affairs
Moshe Giladi

Moshe Giladi

Head of Preclinical Research

NovoCure Office Locations

NovoCure has offices in Fort Collins, Indianapolis, Wilmington, Madison and in 37 other locations
Jersey, JE (HQ)
Le Masurier House, La Rue Le Masurier
Haifa, IL
Shoshanat Ha'Karmel St
Chiyoda-ku, JP
1 Chome-9 Marunouchi, Tōkyō-to 100-6736
Root, CH
D4 Pk., 6039 Root
Portsmouth, US
195 Commerce Way
Show all (42)
Report incorrect company information

NovoCure Financials and Metrics

NovoCure Financials


Revenue (Q1, 2018)

52.1 m

Gross profit (Q1, 2018)

33.9 m

Gross profit margin (Q1, 2018), %


Net income (Q1, 2018)

(20.7 m)

EBIT (Q1, 2018)

(12.7 m)

Market capitalization (14-Jun-2018)

2.9 b

Closing share price (14-Jun-2018)


Cash (31-Mar-2018)

111.6 m
NovoCure's current market capitalization is $2.9 b.
USDQ1, 2018


52.1 m

Cost of goods sold

18.2 m

Gross profit

33.9 m

Gross profit Margin, %

USDQ1, 2018


111.6 m


20.4 m

Current Assets

282.8 m


8.9 m
USDQ1, 2018

Net Income

(20.7 m)

Depreciation and Amortization

2.2 m

Cash From Operating Activities

(16.8 m)

Purchases of PP&E

(737 k)
USDY, 2018

Financial Leverage

2.9 x
Show all financial metrics
Report incorrect company information

NovoCure Online and Social Media Presence

Embed Graph
Report incorrect company information